300016 Stock Overview
Beijing Beilu Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Beijing Beilu Pharmaceutical Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.94 |
| 52 Week High | CN¥8.93 |
| 52 Week Low | CN¥3.58 |
| Beta | 0.42 |
| 1 Month Change | -5.36% |
| 3 Month Change | 0.20% |
| 1 Year Change | -28.92% |
| 3 Year Change | -45.59% |
| 5 Year Change | -45.53% |
| Change since IPO | -6.33% |
Recent News & Updates
Shareholder Returns
| 300016 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 5.8% | 5.6% | 3.1% |
| 1Y | -28.9% | -11.0% | -13.1% |
Return vs Industry: 300016 underperformed the CN Pharmaceuticals industry which returned -11% over the past year.
Return vs Market: 300016 underperformed the CN Market which returned -13.1% over the past year.
Price Volatility
| 300016 volatility | |
|---|---|
| 300016 Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 300016's share price has been volatile over the past 3 months.
Volatility Over Time: 300016's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 952 | Xu Wang | www.beilu.com.cn |
Beijing Beilu Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. The company's products include contrast agents, central nervous system products, and oral anti-diabetic drugs. Beijing Beilu Pharmaceutical Co., Ltd.
Beijing Beilu Pharmaceutical Co., Ltd Fundamentals Summary
| 300016 fundamental statistics | |
|---|---|
| Market cap | CN¥2.43b |
| Earnings (TTM) | -CN¥72.81m |
| Revenue (TTM) | CN¥910.19m |
2.7x
P/S Ratio-33.4x
P/E RatioIs 300016 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300016 income statement (TTM) | |
|---|---|
| Revenue | CN¥910.19m |
| Cost of Revenue | CN¥510.84m |
| Gross Profit | CN¥399.34m |
| Other Expenses | CN¥472.15m |
| Earnings | -CN¥72.81m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 43.88% |
| Net Profit Margin | -8.00% |
| Debt/Equity Ratio | 46.5% |
How did 300016 perform over the long term?
See historical performance and comparison